ImmunityBio, Inc. IBRX Reportable Segment — Research and Development Expense, Internal
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ResearchAndDevelopmentExpenseInternal.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — research and development expense, internal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — research and development expense, internal?
- ImmunityBio, Inc. (IBRX) reported reportable segment — research and development expense, internal of $47.91M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — research and development expense, internal changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — research and development expense, internal increased by 12.1% year-over-year, from $42.72M to $47.91M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — research and development expense, internal?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — research and development expense, internal has grown at a 7.0% compound annual growth rate (CAGR), from $165.24M to $189.29M.
- What does reportable segment — research and development expense, internal mean?
- Reflects the costs incurred for R&D activities performed in-house by the company's own staff and facilities. This highlights the company's commitment to maintaining proprietary research capabilities.